Dr. Eric Fombonne

Eric Fombonne

Professor
Oregon Health and Science University

Eric Fombonne is director of autism research at the Institute on Development and Disability at Oregon Health and Science University. He trained in child and adolescent psychiatry in France and has held appointments as clinical scientist at the National Institute of Health and Medical Research in France; senior lecturer and reader at the Institute of Psychiatry and Maudsley Hospital at King’s College London in the United Kingdom (1993-2001); and tenured professor of psychiatry, head of the child psychiatry division and Canada research chair in child psychiatry at McGill University in Canada  (2001-2012). Fombonne has a long experience of clinical work with children with autism and their families over the lifespan and has been also directing clinical services for teenagers with depression. His research on developmental disorders and child and adolescent psychiatric disorders encompasses clinical longitudinal and population-based epidemiological studies, clinical trials and genetic studies. He has published more than 300 articles in peer-reviewed journals and 40 chapters in books. He is past associate editor of the Journal of Autism and Developmental Disorders (1994-2004) and is currently joint editor of the Journal of Child Psychology and Psychiatry. He is also on the editorial board of several other journals in the field of autism and child psychiatry.

 

From this contributor

Explore more from The Transmitter

Cell population in brainstem coordinates cough, new study shows

The work also adds to a growing body of evidence showing that mice, and their genetic toolbox, can be used to study cough.

By Calli McMurray
6 September 2024 | 5 min read
Capitol building
Spectrum Microphone

In updated U.S. autism bill, Congress calls for funding boost, expanded scope

The current Autism CARES Act sunsets in late September.

By Rachel Zamzow
5 September 2024 | 5 min listen
Illustration of ketamine blocking open ion channels in active NMDA receptors, quieting the cells and disrupting downstream signaling involved in depression.

Ketamine targets lateral habenula, setting off cascade of antidepressant effects

The drug’s affinity for overactive cells in the “anti-reward” region may help explain its rapid and long-lasting results.

By Olivia Gieger
4 September 2024 | 6 min read